HotPennyStockNews.com is devoted to fetch you the most exclusive stocks in the market today. Apart from scanning the markets for the most underrated stocks. We propel those victors directly to your email inbox first ahead of the rest of the marketplace gets a prospect.
Los Angelas, CA -- (SBWIRE) -- 01/02/2013 -- Hemispherx BioPharma, Inc (NYSEAMEX:HEB) shares fell 7.45% to $0.251. On Dec. 29, Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Hemispherx Biopharma. The investigation focuses on whether the Company and its executives violated federal securities laws by issuing a series of materially false and misleading statements regarding the efficacy of Hemispherx’s lead product, Ampligen(R) (“Ampligen”), a drug intended for the treatment of Myalgic Encephalomylitis/Chronic Fatigue Syndrome.
Is HEB A Solid Investment At These Levels? Find Out Here
Oncothyreon Inc (USA) (NASDAQ:ONTY) shares increased 4.35% to $1.92 in yesterday’s session. The company, on Dec. 19, announced that the pivotal Phase 3 clinical trial of L-BLP25 (formerly referred to as Stimuvax®) known as START did not meet its primary endpoint of an improvement in overall survival in patients with unresectable, locally advanced stage IIIA or stage IIIB non-small cell lung cancer (NSCLC). The trial was conducted by Merck Serono, a division of Merck KGaA of Darmstadt, Germany, under a license agreement with Oncothyreon.
What Are ONTY’s Charts Signaling For Traders? Find Out Here
Skullcandy Inc. (NASDAQ:SKUL) is trading down .78 to $7.05. SKUL hit a 52-week low today. The company, on Dec. 17, has unveiled the Navigator headphone from its in-house product development team-a streamlined, compact on-ear sibling to the brand’s iconic over-ear Aviator headphone. Much like its predecessor, the Navigator’s design is optics-inspired and lightweight in construction, offering a perfect balance of style and performance. With a custom-designed, finely tuned REX40™ driver, the Navigator delivers an extremely smooth frequency to match the tightly controlled design construction.
Has SKUL Found The Bottom And Ready To Gain Momentum? Find Out Here
Generex Biotechnology Corporation (OTC:GNBT) was a volume gainer of 1.92 million shares, compared to average trading capacity of 1.52 million shares.
GNBT closed the session at $0.0250 as it advanced +4.17%. The 5 days performance showed it as a percentage loser as it dropped about -7.41%.
Outstanding shares of GNBT remained 372.06 million and the beta figure stayed at 1.61.
How Should Investors Trade GNBT Now? Find Out Here
Neither HotPennyStockNews.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by HotPennyStockNews.com, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation. HotPennyStockNews.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through HotPennyStockNews.com. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to lose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein..
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-321-1250 (International)